ERIC H.C. WEI

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

LISATA THERAPEUTICS, INC.

Filing Date Source Excerpt
2012-09-07 Pursuant to the terms of the Erye Merger agreement, Eric H.C. Wei was appointed to the NeoStem Board of Directors upon the consummation of the Erye Merger in October 2009. ... The Audit Committee consists of four directors: Mssrs. Bernstein (chairman), Myers, Berman and Greenacre. ... Eric Wei 2011 $60,000 total compensation.
2013-08-30 Eric H.C. Wei was appointed to the NeoStem Board of Directors upon the consummation of the Erye Merger in October 2009... Mr. Wei serves on the Audit Committee... The following table sets forth director compensation for 2012 showing total compensation of $92,400.
2014-08-29 Pursuant to the terms of the agreement governing our acquisition our former Erye subsidiary, Eric H.C. Wei was appointed to the NeoStem Board of Directors upon the consummation of the Erye Merger in October 2009. From July 2006 to March 2007, Mr. Wei served as a director of CBH. Eric H.C. Wei is one of the founders and the Managing Partner of RimAsia Capital Partners, L.P. a private equity firm focused on the pan-Asian mid-market sector and a greater-than-5% stockholder of NeoStem.
2016-05-10 Eric H.C. Wei Eric H.C. Wei was appointed to the Board in October 2009... The Audit Committee consists of three directors: Messrs. Wei (chairperson), Myers and Klosk... Our Compensation Committee consists of three directors: Messrs. Klosk (chairperson), Myers and Wei... The following table sets forth information on all compensation to Caladrius' directors (other than as reflected in the Summary Compensation Table) for the year ended December 31, 2015... Eric C. Wei (5) $40,000 $67,360 $0 $107,360

Data sourced from SEC filings. Last updated: 2025-08-30